One-Shot gene therapy aims to restore sight in genetic blindness trial
NCT ID NCT07406854
Summary
This study is testing a one-time gene therapy injection into the eye to see if it can improve vision in people with a specific genetic form of Leber's hereditary optic neuropathy (LHON), which causes severe vision loss. It will involve about 95 participants, aged 12 to 75, who have had reduced vision for more than 6 months but less than 10 years. The main goal is to see if the treatment is safe and if it leads to meaningful vision improvement compared to a sham (pretend) injection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY (LHON) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.